20.09.2023 An event focused on the implementation of EU HTA Regulation with participants from Greece, Bulgaria, Cyprus and Romania was held on 18th September in Athens. As a representative of the NCPR, I had the opportunity to participate in the panel discussion: "The National perspective - Expectations, opportunities and challenges ahead" where together with local experts from each country we discussed the current state of play in each national system and the challenges we still have to overcome for the successful implementation of HTAR.
NCPR is a full member of HAG 16.01.2023. The National Council, as of January 2023, is a full member of the HTA Agencies Group (HAG). Founded in September 2021, HAG is an independent group of 32 European health agencies and institutions working together to develop strategic cooperation in the field of Health Technology Assessment. The rapid growth of the HAG is testament to the willingness of HTA institutions across Europe to collaborate in areas of vital mutual interest. In the process of implementing Regulation 2021/2282 on HTA, the European Commission and all members remain steadfast in their commitment to work together to develop strategic cooperation in the field of HTA.
Published Regulation (EU) 2021/2282 22.12.2022 On 15 December 2021, Regulation (EU) 2021/2282 of the European Parliament and of the Council on Health Technology Assessment and amending Directive 2011/24/EU (HRT Regulation) was published in the Official Journal of the European Union . The Regulation on HTA, and in particular Art. 29 of it, foresees the creation of a Stakeholder network, which will support the work of the HTA Coordination Group and its subgroups. The Stakeholder Network will be open to both civil society organizations and stakeholder organizations, in particular patient associations, consumer organizations, non-governmental organizations in the field of health care, health technology developers, as well as health professionals, incl. representatives of scientific circles. The purpose of the Stakeholder network is to facilitate the dialogue between all interested entities and the Coordination Group. This mechanism ensures transparency and stakeholder participation in one of the most important parts of the evaluation of new health technologies, namely their clinical evaluation, which will allow the public to express their position at a very early stage of their evaluation.